September 2026
M	T	W	T	F	S	S
	1	2	3	4	5	6
7	8	9	10	11	12	13
14	15	16	17	18	19	20
21	22	23	24	25	26	27
28	29	30

Bruno Pougault: The Thin Line Between Bleeding and Clotting

Bruno Pougault/LinkedIn

Jun 24, 2026, 02:51

Bruno Pougault: The Thin Line Between Bleeding and Clotting

Bruno Pougault, Global Marketing Hemostasis Product Manager at HORIBA, shared on LinkedIn:

“Precision in Hemostasis: The Thin Line Between Bleeding and Clotting

Behind every safe surgery, successful cancer treatment, or managed cardiovascular disease lies a critical, yet often unseen hero: the Hemostasis Laboratory.

In clinical practice, the stakes couldn’t be higher. A fraction of a second in clotting time or a slight variation in factor levels makes the difference between a catastrophic hemorrhage and a fatal thrombotic event.

Yet, the clinical value of hemostasis diagnostics depends entirely on uncompromising analytical quality and global standardization.

Swipe through the carousel below to discover why high-quality medical diagnostics are our strongest shield against hemorrhagic and thrombotic risks.

Key Highlights Inside:

The Power of Plasma: Why plasma analysis remains the gold standard for accuracy, reproducibility, and avoiding cellular interference compared to whole blood.
The Standardization Challenge: The critical clinical need for international harmonization in assays like D-Dimer to ensure reliable patient stratification globally.
Risk Prevention: How robust central lab data empowers clinicians to make safer, personalized therapeutic decisions before complications arise.

In the era of modern medicine, diagnostic excellence isn’t just about running tests—it’s about ensuring absolute reliability when patients’ lives are on the line.”

Bruno Pougault: The Thin Line Between Bleeding and Clotting